Abstract 322P
Background
There is limited evidence regarding the prognostic value of the three-tier chemotherapy response score (CRS) in advanced epithelial ovarian cancer (EOC). We aimed to evaluate the impact of CRS on survival in advanced EOC.
Methods
This prospective single-centre study included consecutive women with stage IIIC-IV EOC who underwent interval debulking surgery (IDS) after neoadjuvant chemotherapy (NACT) at Tata Medical Center between March 2021 and June 2022. Clinical characteristics, progression-free survival (PFS), and overall survival (OS) were compared between the CRS groups.
Results
Among the 102 women treated with NACT followed by IDS, CRS 1 was found in 16 (15.7%), CRS 2 in 66 (64.7%), and CRS 3 in 20 (19.6%). Age, stage, and BRCA status were not different across CRS groups. The patients with CRS 3 had significantly longer PFS than the other CRS groups (median PFS 17 months, 19.8 months, and not reached for CRS 1, 2, and 3, respectively, P = 0.001). Estimated OS was also significantly longer in those with CRS 3 (median OS 22.2 months, 33 months, and not reached for CRS 1, 2, and 3, respectively, P = 0.035). The PFS and OS differences remained statistically significant in univariate and multivariate analyses.
Conclusions
Chemotherapy response score 3 was associated with improved survival in advanced EOC treated with NACT. The prognostic value of CRS can be used in future studies of response-adapted adjuvant or maintenance treatment in advanced EOC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract